2013 ACCF/AHA Guideline for the Management of Heart Failure

Yancy, Clyde W.; Jessup, Mariell; Bozkurt, Biykem; Butler, Javed; Casey, Donald E.; Drazner, Mark H.; Fonarow, Gregg C.; Geraci, Stephen A.; Horwich, Tamara B.; Januzzi, James L.; Johnson, Maryl R.; Kasper, Edward K.; Levy, Wayne C.; Masoudi, Frederick A.; McBride, Patrick E.; McMurray, John J.V.; Mitchell, Judith E.; Peterson, Pamela N.; Riegel, Bárbara; Sam, Flora; Stevenson, Lynne Warner; Tang, W.H. Wilson; Tsai, Emily J.; Wilkoff, Bruce L.

doi:10.1016/j.jacc.2013.05.019

Cited by 6,999 publications

(1,953 citation statements)

References 873 publications

Supporting

Mentioning

1,854

Contrasting

Unclassified

Order By: Relevance

“…Future studies should use the same EF strata as those proposed in the 2013 AHA/ACC guidelines2 to ensure that studies can be adequately compared. Further work is needed to understand the impact of various chronic conditions and sociodemographic, psychosocial, and clinical factors on the overall mortality of patients with ADHF by currently recommended EF strata.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…To better understand and characterize the epidemiology of this increasingly prevalent clinical syndrome, a classification schema for heart failure (HF) has been recently created based on ejection fraction (EF) findings 2. The 2013 American Heart Association/American College of Cardiology (AHA/ACC) guidelines characterized 3 EF strata as preserved EF (pEF; ≥50%), reduced EF (rEF; ≤40%), and borderline preserved EF (BpEF; 41–49%) 2. This new classification schema was recommended because several research groups had used different EF cutoffs for differentiating patients with pEF from those with rEF findings, producing varying study results and difficulties in interpretation and extrapolation.…”

Section: Introductionmentioning

confidence: 99%

“…Many of these earlier studies examined the role of various prognostic factors in patients with HF that had not further been stratified according to EF findings, and among those that did,11, 13, 14, 15, 16, 17 none used the 2013 AHA/ACC guidelines recommending specific EF cut points 2. Furthermore, few data exist on the prognosis or the factors associated with poor long‐term prognosis for patients with BpEF values, especially from the more generalizable perspective of a population‐based investigation.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Magnitude of and Prognostic Factors Associated With 1‐Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings

Coles

Tisminetzky

Yarzebski

et al. 2015

JAHA

View full text Add to dashboard Cite

BackgroundLimited data exist about the magnitude of and the factors associated with prognosis within 1 year for patients discharged from the hospital after acute decompensated heart failure. Data are particularly limited from the more generalizable perspective of a population‐based investigation and should be further stratified according to currently recommended ejection fraction (EF) findings.Methods and ResultsThe hospital medical records of residents of the Worcester, Massachusetts, metropolitan area who were discharged after acute decompensated heart failure from all 11 medical centers in central Massachusetts during 1995, 2000, 2002, 2004, and 2006 were reviewed. The average age of the 4025 study patients was 75 years, 93% were white, and 44% were men. Of these, 35% (n=1414) had reduced EF (≤40%), 13% (n=521) had borderline preserved EF (41–49%), and 52% (n=2090) had preserved EF (≥50%); at 1 year after discharge, death rates were 34%, 30%, and 29%, respectively (P=0.03). Older age, a history of chronic obstructive pulmonary disease, systolic blood pressure findings <150 mm Hg on admission, and hyponatremia were important predictors of 1‐year mortality for all study patients, whereas several comorbidities and physiological factors were differentially associated with 1‐year death rates in patients with reduced, borderline preserved, and preserved EF.ConclusionsThis population‐based study highlights the need for further contemporary research into the characteristics, treatment practices, natural history, and long‐term outcomes of patients with acute decompensated heart failure and varying EF findings and reinforces ongoing discussions about whether different treatment guidelines may be needed for these patients to design more personalized treatment plans.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Magnitude of and Prognostic Factors Associated With 1‐Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings

Coles

Tisminetzky

Yarzebski

et al. 2015

JAHA

View full text Add to dashboard Cite

show abstract

“…Acute heart failure (AHF) is the most common cause of hospitalization in patients 65 years and older 1, 2. In part due to the ageing of the population and more effective treatment of chronic heart failure (HF), its prevalence is expected to increase by 25% over the next 20 years 3 and the problem has expanded worldwide 4, 5.…”

Section: Introductionmentioning

confidence: 99%

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study

Teerlink

Voors

Ponikowski

et al. 2017

European J of Heart Fail

108

103

View full text Add to dashboard Cite

Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin‐2, a hormone with vasodilatory and end‐organ protective effects believed to play a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX‐AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. Compared to placebo, serelaxin also reduced worsening heart failure (WHF) by 47% through day 5 and both all‐cause and cardiovascular mortality by 37% through day 180. RELAX‐AHF‐2 ( ClinicalTrials.gov NCT01870778) is designed to confirm serelaxin's effect on these clinical outcomes. RELAX‐AHF‐2 is a multicentre, randomized, double‐blind, placebo‐controlled, event‐driven, phase 3 trial enrolling ∼6800 patients hospitalized for AHF with dyspnoea, congestion on chest radiograph, increased natriuretic peptide levels, mild‐to‐moderate renal insufficiency, and systolic blood pressure ≥125 mmHg. Patients are randomized within 16 h of presentation to 48 h intravenous infusions of serelaxin (30 µg/kg/day) or placebo, both in addition to standard of care treatments. The primary objectives are to demonstrate that serelaxin is superior to placebo in reducing: (i) 180 day cardiovascular death, and (ii) occurrence of WHF through day 5. Key secondary endpoints include 180 day all‐cause mortality, composite of 180 day combined cardiovascular mortality or heart failure/renal failure rehospitalization, and in‐hospital length of stay during index AHF. The results from RELAX‐AHF‐2 will provide data on the potential beneficial effect of serelaxin on cardiovascular mortality and WHF in selected patients with AHF.

show abstract

Association of Blood Transfusion With Increased Mortality in Myocardial Infarction

Chatterjee¹,

Wetterslev²,

Sharma³

et al. 2013

JAMA Intern Med

204

View full text Add to dashboard Cite

2013 ACCF/AHA Guideline for the Management of Heart Failure

Cited by 6,999 publications

References 873 publications

Magnitude of and Prognostic Factors Associated With 1‐Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings

Magnitude of and Prognostic Factors Associated With 1‐Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study

Association of Blood Transfusion With Increased Mortality in Myocardial Infarction

Contact Info

Product

Resources

About